$Eli Lilly(LLY.US) (-8% pre-mkt, long position) as disappointing data on its new weight loss pill overshadowed a solid 2Q sales beat and good 3Q guidance from its current injectable obesity drugs. In Phase 3 trials, the new pill's results showed lower weight loss and higher rates of nausea and vomiting, side effects associated with GLP-1 drugs. Lilly's data raise doubts over whether the once daily pill, called orforglipron and which is expected for 2026 release can meet Wall Street's estimates of $12B in annual sales by 2030.
Once a day pills are a key part of reaching more patients in the market that’s expected to grow to $95 billion by 2030. In Lilly’s pill study, patients on the highest dose shed roughly 11% of their body weight, or 25 pounds, the company said. In late-stage trials, patients on an oral version of Novo’s Wegovy lost about 16% of their weight over a 68-week period. About 10% of patients dropped out of the study due to side effects such as nausea and vomiting. Orforglipron is easier to manufacture than its current injectable Zepbound and is expected to be a cheaper option for patients.3Q guidance:- Rev $60.0B - $62.0B, saw $58.0B to $61.0b, vs 60.1B est. - Adj EPS $21.75 to $23.00, saw $20.78 to $22.282Q results:- Adj EPS $6.31 vs. $5.57 expected- Rev $15.56B, +38% y/y, vs $14.7B est.- Zepbound Rev $3.38B vs $3.07B est- Mounjaro Rev $5.20B vs $4.50B est.- Trulicity Rev $$1.09B vs $1.04B estConf call 830ETThe copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
